Skip to content
Saturday 8 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,901.09
+0.31%
DAX
26,319.45
+0.69%
CAC 40
8,714.93
+0.17%
STOXX 50
6,523.86
+0.33%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE

pharmaceuticals

  • How Astrazeneca became the London Stock Exchange’s newest £200bn firm

    August 14, 2024

    Astrazeneca has become the most recent UK-listed company to achieve a market valuation of £200bn, a landmark achievement for both the pharmaceutical giant and the London Stock Exchange, as investors have been won over by its ambition and success with cancer treatments. The company’s shares rose by 1.1 per cent on Tuesday, propelling its market [...]

  • Hikma given shot in the arm by ‘excellent’ double-digit growth

    August 8, 2024

    Pharmaceutical firm Hikma has hiked its dividend and raised its guidance having hailed an “excellent” first half of the year. The Jordanian-founded FTSE 100 pharma firm, which in June bolstered its injectables offering with the purchase of Danish rival Xellia, posted a double-digit revenue rise of 10 per cent, raking in $1.6bn (£1.3bn) in the [...]

  • GSK wins latest Zantac trial as jury finds drug did not cause woman’s cancer

    August 6, 2024

    GSK - formerly GlaxoSmithKline - has won its latest trial over whether its most popular drug caused cancer on Monday, after a jury found it was not the root cause of an American woman's illness.

  • GSK: Pharma giant raises guidance after second quarter sales give shot in the arm

    July 31, 2024

    London-listed pharma giant GSK has raised its guidance after a strong second quarter beat market expectations, boosted by its cancer and HIV portfolio. Total sales in the second quarter of 2024 reached £7.9bn, an increase of 13 per cent year on year. Core operating profit at the pharma company rose by 18 per cent on [...]

  • Astrazeneca shares fall after FTSE giant’s forecast lift fails to inspire

    July 25, 2024

    In the first half of 2024, Astrazeneca reported an 18 per cent year-on-year increase in total revenue, reaching $2.6bn (£2bn).

  • Eco Animal Health beats expectations thanks to Americas growth

    July 15, 2024

    Animal vaccine firm Eco Animal Health beat earnings expectations despite continuing volatility in currency, thanks largely to its "robust" demand for its flagship vaccine and consistent market leading position.

  • Indivior shares plunge after US move and profit warning

    July 9, 2024

    Indivior lowered its annual adjusted operating profit forecast and shares in the company plunged.

  • British Patient Capital invests £90m London biotech company

    July 8, 2024

    British Patient Capital recently also invested £10m into biotech firm Curve Therapeutics to support its cancer drug discovery technology.

  • UK less ready for next pandemic than before Covid – Oxford vaccinologist

    July 3, 2024

    The UK's state apparatus is less prepared to deal with a pandemic today than it was before Covid, one of the professors in charge of the Oxford Astrazeneca vaccine rollout has warned.

  • GSK to pay Curevac £1.2bn for full rights to develop and commercialise mRNA vaccines

    July 3, 2024

    GSK will assume full control of developing and manufacturing the candidate vaccines and will have worldwide rights to commercialise them.

Posts pagination

  • Previous
  • Page 1
  • …
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • …
  • Page 20
  • Next

Trending Articles

  • WPP slashes jobs as revenue continues to fall

  • Liverpool owners tipped to sell – but not to Amazon boss Bezos – by former CEO

  • Revolut founder’s wealth set to balloon amid talks of share award at $500bn valuation

  • Starling plans to ‘come out swinging’ in diversification bid

  • As it happened: Stocks rise despite new tensions in Strait of Hormuz; Oil price climbs

MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook